can be found in normal cervix, thymus, lung, and estis (2); trace amounts can be found in breast (3), ovary, nd oviduct (4). The testicular heat-stable ALP isoenzyme iffers from PLAP by its clearly enhanced inhibition by .leucine and by its lesser electrophoretic mobility, and herefore it has been referred to as #{176}PLAP-like ALP' (2, 5) r, more recently, as "germ-cell ALP" (GCAP) (6).
ntibody at a lower affinity than was seen for the more ommon PI..AF' phenotypes. Antibody affinity is higher for the ee hydrophilicdimenc forms of PLAPand GCAP,and is not ifluenced by the degree of glycation. In serum or tissue ixtracts, measurement of PLAP or GCAP is most nearly ccurate when immunoincubations are performed at 37#{176}C, ,ith use of antibodies 327 and 7E8, respectively.In addition, orrect measurements are achieved only when, during imunobinding, serum is incubated with an equal volume of teoxycholate (9 g/L final concentration).
4dltlonal Keyphrasos: tumor marker assessment of mem-
rane enzymes cancer isoenzymes and phenotypes
Human alkaline phosphatases (ALP, EC 3.1.3.1) are a oup of membrane-bound metalloenzymes present as oenzymes in selected tissues and cells (1). Apart from its bundant presence in placental microvilli, small amounts f the heat-stable placental isoenzyme (placental ALP, LAP) can be found in normal cervix, thymus, lung, and estis (2); trace amounts can be found in breast (3), ovary, nd oviduct (4). The testicular heat-stable ALP isoenzyme iffers from PLAP by its clearly enhanced inhibition by .leucine and by its lesser electrophoretic mobility, and herefore it has been referred to as #{176}PLAP-like ALP' (2, 5) r, more recently, as "germ-cell ALP" (GCAP) (6).
PLAP displays a high degree of polymorphism. More than 8 electrophoretically distinct allelic variants have been escribed, but approximately 98% of all placental phenopea are controlled by three common alleles: 1 (S), 2 (F), d 3 (1) (7). The application of monoclonal antibodies Lised against FLAP has provided evidence that GCAP is ructurally different from PLAP and also exhibits a specific ,netic polymorphism (8), although the two isoenzymes are % homologous (6).
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PLAP or GCAP can be expressed in high amounts in ovarian tumors and in seminomas, from where these membrane proteins can be released into the patient's serum and ascites to detectable concentrations (4, 9, 10). Several studies have evaluated serum FLAP or GCAP as a tumor marker for the diagnosis of ovarian cancer and seminOma, measuring its activity after heat treatment of the serum (11), by radioimmunoassay (12), or by enzyme immunoassays (13). These studies have indicated that PLAP and (or) GCAP is present in the serum of about 49% of ovarian-tumor patients and that GCAP is present in that of 72% of seminoma patients (13). However, they also showed that smoking is the main source of aspecific increases in FLAP or GCAP, related to the presence of heat- Antigen de,glycation: A PLAP (type 2) and GCAP extract (100 U/L) were incubated at 37#{176}C for 24 h with a 1 to 4 mixture of the following glycosidases in 0.25 molJL imidazole buffer, pH 6.5, containing, per liter, 10 g of Triton X-100, 1 mmol of benzamidine, 250 kU of aprotinin, 1 pniol of leupeptide, and 50 mmol of KC1: and anti-intestinal ALP monoclonal antibodies 1AP250 (high affinity) and IAP151 (intermediate affinity) (22) were raised in the laboratory according to the procedure described.
Affinity measurements by enzyme antigen immunoassay (EAIA):
The EAJA was performed essentially as described (23) , with some slight modifications.
Nonspecific binding sites of microtiter plates, precoated with rabbit anti-mouse IgG antiserum, were blocked by exposure to a 10%-saturated solution of casein in phosphate-buffered saline (PBS), Labeling of monoclonal antibodies with biotin: Antibod ies 7E8, 327, and 17E3 (0.25 g/L) were biotinylated upoii addition of N-hydroxysuccinimide biotin ester in 0.1 mol/I NaHCO3 buffer, pH 8.5. After the mixture was incubated at room temperature for 1 h, free biotin groups werE removed by gel ifitration on Sephadex G-25. A fivefold molar excess of biotin ester to antibody was found to lx optimal in preserving the immunological integrity of thE antibody and in providing a sufficient biotin label in a sandwich ELISA (see below).
Competition assays in a sandwich ELJSA: FLAP (type 1, 250 U/L) was incubated for 4 h at 37#{176}C in microtiter plates that had been precoated with polyclonal rabbit anti-humaii FLAP antiserum.
After washing, biotin-labeled monoclona] antibodies (2.5 mg/L) were incubated overnight at 4#{176}C in the wells of the plates in the presence of increasing concentrations (0-50 mgfL) of unlabeled antibody. Bound biotin. ylated antibodies were revealed with the avidin-biotin-. peroxidase complex stained with 1 mmol/L ARTS in 0.2 mol/L phosphate-0.1 moIJL citrate buffer, pH 4.3, containing 20 mg of H202 per liter.
Analytical recovery from human serum: FLAP immunobinding was quantitatively studied in 24 progressively diluted sera supplemented with purified FLAP (1 U/L), and in 46 pregnancy sera, with various lipoprotein concentrations. Furthermore, immunobinding of liver ALP and in. testinal ALP was evaluated in 10 and 17 fresh se respectively. The binding of FLAP, liver ALP, and intest ALP was studied for undiluted sera (200 .&L), in th presence or absence of DOC, 9 g/L. For DOC-supplemen sera, recovery upon heat treatment (56 #{176}C for 30 mm), upo dilution, or upon addition of detergents (from 0 to 10 g/L was calculated as follows:
In the final assay configuration (100 p1 of serum + 100 of DOC, 18 g/L), intra-assay variations were determined fo 22 of these supplemented sera, each pipetted six times the same microtiter plate, whereas interassay variatio were estimated on two samples, each pipetted twice in for binding to type 1 PLAP, which was bound on microtiter plates precoated with a rabbit antiserum to humanPLAP ments of relative affinities. B/F ratios calculated for monoclonal antibodies 7E8, 17E3, 327, and E6 did not consistently change for various stages of deglycation of FLAP and GCAP. Also, the low GcAP-binding by 17E3 could not be enhanced by sugar removal (Table 1) .
Relative affinities for PLAP and for GCAP phenotypes: Table 2 summarizes the relative affinities (B/F) of antibodies 7E8, 17E3, 327, and E6 for the more common FLAP phenotypes as measured at 4#{176}C (for mniimnl discrimination between phenotypes, see below). Antibody E6 clearly distinguishes between the electrophoretically defined FLAP phenotypes 1, 2-1, and 2, with a high, intermediate, and low affinity, respectively.
In all cases, antibodies 327 and 17E3 have lower affinities than do 7E8, but none of these three antibodies discriminates between most of the electrophoretic FLAP variants. Nevertheless, with 7E8 and 327, two subgroups could be identified within the type 1 group, having a two-to threefold difference in affinity.
Heat-stable ALP, extracted from 13 testicular tumors and from one ovarian tumor, and the heat-stable ALP present in a cancer patient's serum all showed approximately 50% inhibition of enzymatic activity in the presence of 0.35 mmol of L-leucine per liter, confirming the FLAP-like nature of these samples. In addition, their electrophoretic mobilities in starch gel were considerably lower than those of FLAP, both before and after treatment with neuraminidase. The relative affinities of these tumor GCAP isoenzymes for the same panel of monoclonal antibodies are represented in Table 3 . In general, the highest affinity for (Table 3) .
Relative affinities as a flznction of temperature: Regardless of their phenotype, these 15 GCAP extracts and 17 FLAP extracts were incubated with the monoclonal antibodies 7E8, 327, 17E3, and E6 in an EAIA-configuration, both at 4 and at 37#{176}C, and B/F ratios were calculated (Figure 3) . Monoclonal antibodies 7E8 and E6 have a higher affinity for FLAP phenotypes at 4#{176}C than at 37 #{176}C. In contrast, antibody 327 has an almost threefold higher affinity at 37#{176}C than at 4#{176}C. Monoclonal antibody 17E3 displays an equal but low affinity for FLAP phenotypes at 4 and at 37#{176}C.
GCAP phenotypes
react with a two-to threefold lowe: affinity with all antibodies as compared with i'LP pheno types. As was true for FLAP phenotypes, relative reactiv ities with antibody 327 were threefold higher at 37 #{176}C thai at 4#{176}C and GCAP phenotypes reacted to a lesser extent witi antibody 7E8 at 37#{176}C than at 4#{176}C. Antibody 17E3 wa almost unreactive and E6 was equally potent at boti temperatures tested.
Furthermore, increasing the temperature to 37#{176}C re duced the variation in affinity between phenotypes fo; antibodies 7E8, E6, and 327 within both groups of isoen zymes (for FLAP, the range in standard deviation decrease from 33-63% at 4#{176}C to 20-31% at 37#{176}C; for GCAP i decrease from 37-78% at 4#{176}C to 28-49% at 37#{176}C was seen)
PLAP and OCAP phenotypes in human serum: Wahren e al. (25) have demonstrated that FLAP and GCAP phenotypa found in placenta and tumor extracts can also be found ii serum. In agreement with this observation, we performed i series of B/F measurements at 4#{176}C on 30 heat-inactivatec sera from identified seminoma patients. With antibod 7E8, all GCAP phenotypes reacted with an affinity classifle as high (see Table 3 
ALP detection by detergents:
Re covery studies of fully active purified FLAP added to sever#{225} fresh sara always resulted in important underestimation by as much as 95% of the ALP activity added. However, os heating the supplemented sera (at 56#{176}C for 30 mm) befort the EAIA, or on progressively diluting the supplementec sera (1/4 or 1/8), the recoveries gradually improved to 100't (Table 4) . Because dilution of the serum decreases assa sensitivity, and preheating complicates sample handling, third alternative was sought. Hence, detergents in sever#{225} concentrations were added to the supplemented test serun during incubation.
Non-ionic detergents indeed improvec the PLAP recovery-by as much as 34% for Triton X-1O( and as much as 69% for N-nonyl-$-D-glucopyranoside, eaci at 10 mLIL. The ionic detergent deoxycholate enhancec recoveries even further, up to 100%, and these mnima FLAP recoveries were reached in the EAJA upon miyin' equal volumes of serum (100 L) and DOC (100 tL) to giv a final detergent concentration of 9 g/L (Figure 4) . Moi extensive recovery studies on further-diluted sara, suppli mented with FLAP, confirmed that this DOC concentratio iabled a full enzyme recovery, with an intra-and interasy CV of <3% (Table 4) . The importance of detergent addition during EAIA was rther documented by use of undiluted fresh FLAP-containsara from pregnant women. For these purposes, r'i ding was measured on all four antibodies described, in the absence and in the presence of DOC, 9 gIL ble 5). We observed large variations in the enhancent of pp binding for all the antibodies, but for an vidual sample the enhancement attained for one antiy paralleled that found for all the others. The mean provement (threefold) was likewise comparable for all ibodies. When detergent was included, PLAP measurents of progressively diluted pregnancy sera were linear en measured with all antibodies described, in contrast to Table 4 . AnalytIcal Recovery in EAIA of
PLAP-Suppiemented

Fresh Human Seraa
Recovery, %
Inthe absence of DOC, 200
MLof nativeserum was progressivelydiluted, whereas the optimizeda.iA procedure including DOC necessitated an Initial twofold dilutionof 100 ML of serum with 100 ML of 9 giL DOC solution.
b Forthe assay configuration in the presence of DOC (9 g/L), the intra-assay (n = 22 x 6) and interassay variation (n = 2 x 3)were2.9% ± 1.2% and 2.4% ± 1.7%, respectively. (25) , tI presence of several GCAP phenotypes was confirmed in ti serum of patients with proven testis tumor. It is notewo thy that all GCAP phenotypes found in the serum of tha patients reacted with antibody 7E8 with a relative afflnii classified as high.
Because variations
in affinity between FLAP or (3(11 phenotypes are smaller at 37 #{176}C than at 4 #{176}C, measur ments of the serum PLAP and GCAP concentrations will 1 more nearly accurate at 37 #{176}C. In general, at higher mci bation temperatures, the antigen-antibody affinity d dines slightly (27) . The surprising finding that relatii affinities of PLAP or OCAP for antibody 327 are enhanced 1 a factor of three when the temperature is increased from to 37#{176}C could be explained by an increase in the rate i which antigen and antibody associate, whereas the diss ciation rate was not influenced by temperature (results ii shown). Consequently, at 37 #{176}C, antibodies 7E8 and 327 a equivalent with respect to immunological measurement 1'LAP. However, in view of the results obtained for t relative affinities for GCAP phenotypes in tumoral extrac together with the observation that most serum GCAP p1 notypes are of the "high reactivity" type with antibody 7) our findings suggest that immunological measurement serum GCAP would be most nearly accurate when based an antibody with 7E8 characteristics.
FLAP measurement in fresh sera pointed to a drama underestimation of the enzyme activity in several sera. 1'] effect was observed to a comparable extent for measu ments performed on different anti-FLAP monoclonal antib ice, and it was also encountered during immunodetection some other ALP isoenzymes.
The observed interference serum was only weak, because a mere fourfold dilution the sara enabled us to measure the PLAP isoenzyme ac rately, also in those sara where FLAP initially was mi underestimated. Leans of a high-affinity antibody than when an intermedie-afflnity monoclonal antibody was used, suggesting that e detergent-induced decrease in serum viscosity cannot lely account for the observed improvement in ALP detecon. These findings are in agreement with early data scribing weak interactions between alkaline phosiatases, or 16 other serum enzymes, and low-density lipootein, being easily abolished by several physical proceires that affect the molecular structure of low-density poprotein (28) . Nevertheless, we could not find any corretion between the degree of interference during immu-)bindlng and the concentration of lipophilic components in rum, but in view of the narrow range of these concentraons this is not surprising.
Interference by serum was never )served in sara stored at -20 #{176}C for several months, sugsting an involvement of progressive lipoprotein oxidation 8). The concentration of DOC selected (9 g/L) was suffiently high, even for those sera with a high lipid content. i addition, this fairly high detergent concentration easily Lssociates the high-molecular-mass forms of FLAP or GCAP metimes encountered in the sara of cancer patients (tinzblished findings).
Although dilution, repeated freezing zd thawing, heat treatment, and detergent addition all crease the serum FLAP availability for iminunodetection, re exact nature of the FLAP complex formation in serum ,mains at present unclear. The present paper shows that om an analytical point of view the detection of serum Lacental-type ALP can be made more nearly accurate by tcreasing its availability in serum, choosing an adequate icubation scheme, and using antibodies that minimally Lscriminate between FLAP and GCAP phenotypes.
Future flow-up studies will determine whether FLAP or GCAP, Loneor in combination with other tumor markers, has any iture in the management of tumor patients.
